Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Nat Biomed Eng ; 3(7): 558-570, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-31182836

RESUMEN

The recapitulation of bone formation via the in vitro generation of bone-like nodules is frequently used to understand bone development. However, current bone-induction techniques are slow and difficult to reproduce. Here, we report the formation of bone-like nodules within ten days, via the use of retinoic acid (RA) to induce the osteogenic differentiation of human induced pluripotent stem cells (hiPSCs) into osteoblast-like and osteocyte-like cells that create human bone tissue when implanted in calvarial defects in mice. We also show that the induction of bone formation depends on cell signalling through the RA receptors RARα and RARß, which simultaneously activate the BMP (bone morphogenetic protein) and Wnt signalling pathways. Moreover, by using patient-derived hiPSCs, the bone-like nodules recapitulated the osteogenesis-imperfecta phenotype, which was rescued via the correction of disease-causing mutations and partially by an mTOR (mechanistic target of rapamycin) inhibitor. The method of inducing bone nodules may serve as a fast and reproducible model for the study of the formation of both healthy and pathological bone.


Asunto(s)
Huesos/patología , Huesos/fisiología , Células Madre Pluripotentes Inducidas/patología , Células Madre Pluripotentes Inducidas/fisiología , Osteogénesis/fisiología , Animales , Proteínas Morfogenéticas Óseas , Huesos/efectos de los fármacos , Diferenciación Celular , Células Cultivadas , Regulación de la Expresión Génica , Humanos , Técnicas In Vitro , Células Madre Pluripotentes Inducidas/efectos de los fármacos , Masculino , Ratones , Ratones Desnudos , Ratones SCID , Mutación , Osteogénesis/efectos de los fármacos , Osteogénesis/genética , Fenotipo , Receptores de Ácido Retinoico/efectos de los fármacos , Serina-Treonina Quinasas TOR/efectos de los fármacos , Trasplante , Tretinoina/farmacología , Vía de Señalización Wnt
2.
Atherosclerosis ; 173(2): 301-7, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15064106

RESUMEN

It has been suggested that circulating concentrations of hepatocyte growth factor (HGF) are increased in individuals with vascular endothelial damage, such as in hypertensive patients and subjects with atherosclerosis. Because the influence of genetic variation of HGF has not been examined, we identified single nucleotide polymorphisms (SNPs) in the HGF gene, and investigated the association between these SNPs and blood pressure or carotid atherosclerosis in the Japanese general population. We identified 21 SNPs in the HGF gene by direct sequencing in a test population of 32 Japanese subjects. Among them, considering allele frequency and linkage disequilibrium, three SNPs, C-1652T in the promoter, T43839A in intron 8, and T44222C in intron 9, were genotyped in 2412 members of the Japanese general population randomly selected from the residents in Suita city. None of the three SNPs were significantly associated with blood pressure. After adjusting for age, smoking habits, consumption of alcohol, and the presence of diabetes mellitus and dyslipidemia, female subjects with the T allele of T43839A had more severe carotid atherosclerosis compared to individuals with the A allele. This study provides the first evidence that HGF may be a candidate susceptibility loci that affects the progression of atherosclerosis in Japanese subjects.


Asunto(s)
Enfermedades de las Arterias Carótidas/genética , Predisposición Genética a la Enfermedad/epidemiología , Factor de Crecimiento de Hepatocito/genética , Hipertensión/genética , Polimorfismo Genético , Adulto , Distribución por Edad , Anciano , Alelos , Secuencia de Bases , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Enfermedades de las Arterias Carótidas/epidemiología , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Humanos , Hipertensión/epidemiología , Incidencia , Japón/epidemiología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Análisis Multivariante , Reacción en Cadena de la Polimerasa/métodos , Pronóstico , Medición de Riesgo , Muestreo , Índice de Severidad de la Enfermedad , Ultrasonografía Doppler
3.
Am J Hypertens ; 15(11): 927-31, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12441210

RESUMEN

BACKGROUND: Nifedipine has been reported to cause impairment of insulin sensitivity. But recently a controlled-released formulation of nifedipine (nifedipine-GITS) has been reported that it could improve insulin sensitivity. METHODS: We evaluated insulin sensitivity in two groups of essential hypertensive subjects before and after treatment with either long-acting nifedipine (nifedipine-CR, Adalat CR tablets; Bayer Yakuhin, Osaka, Japan) (n = 10) or metoprolol (n = 9). Insulin sensitivity was evaluated from the steady-state plasma glucose (SSPG) level measured at the steady-state insulin level (20 to 30 microU/mL) using a modification of the SSPG method previously reported. RESULTS: The SSPG was initially high, but was significantly reduced by nifedipine-CR treatment (from 133 +/- 14 mg/dL to 95 +/- 8 mg/dL). However, SSPG was not significantly altered by treatment in the metoprolol group (from 103 +/- 15 mg/dL to 119 +/- 12 mg/dL). CONCLUSIONS: Our results indicate that the long-acting nifedipine (nifedipine-CR) is associated with improved insulin sensitivity.


Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Glucemia , Bloqueadores de los Canales de Calcio/uso terapéutico , Hipertensión/tratamiento farmacológico , Resistencia a la Insulina , Insulina/sangre , Metoprolol/uso terapéutico , Nifedipino/uso terapéutico , Anciano , Área Bajo la Curva , Bloqueadores de los Canales de Calcio/administración & dosificación , Preparaciones de Acción Retardada , Ácidos Grasos no Esterificados/sangre , Femenino , Prueba de Tolerancia a la Glucosa , Humanos , Hipertensión/sangre , Cetonas/sangre , Masculino , Persona de Mediana Edad , Nifedipino/administración & dosificación , Resultado del Tratamiento
4.
J Diabetes Complications ; 16(1): 19-23, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-11872361

RESUMEN

Insulin resistance and hyperinsulinemia have been observed in over 70% of the nonobese, nondiabetic subjects with essential hypertension (HT). Alpha-1 blockers, ACE-antagonists, long-acting Ca blockers including nifedipine CR, some form of beta-blockers, tilisolor, which is reported to increase blood flow, improve insulin sensitivity when blood pressure is better controlled. Decrease of serum potassium during insulin sensitivity test and intraplatelet free Ca2+ concentration is positively and negatively correlated with insulin sensitivity, respectively. Blood pressure is correlated with insulin resistance, which is also observed in secondary HT. The resistance is correlated with salt sensitivity as well as impaired nocturnal fall of blood pressure. These suggest the possible association of insulin resistance with altered intracellular cation metabolism. Insulin resistance and associated hyperinsulinemia have been observed in effort as well as vasospastic angina pectoris (VSAP), atherothrombotic cerebral infarction, and in ASO without obesity, HT, or diabetes, suggesting the resistance resulting from endothelial dysfunction. Insulin resistance has been observed in heart failure and is correlated with angiotensin II. Resistance is also observed in hypertrophic cardiomyopathy and is partially correlated with TNF-alpha. These results indicate that insulin resistance seem to be multifactorial. An effort to normalize insulin sensitivity is crucial to eliminate multiple risk factors as well as to prevent the progression of atherosclerotic vascular lesions.


Asunto(s)
Enfermedades Cardiovasculares/fisiopatología , Hipertensión/fisiopatología , Resistencia a la Insulina/fisiología , Antihipertensivos/clasificación , Antihipertensivos/uso terapéutico , Humanos , Hiperinsulinismo/fisiopatología , Hipertensión/tratamiento farmacológico , Modelos Biológicos
5.
Cancer Res ; 74(22): 6531-41, 2014 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-25273088

RESUMEN

Osteosarcoma is a malignant bone tumor in children and adolescents characterized by intrinsic therapeutic resistance. The IGF2 is expressed at elevated levels in osteosarcoma after treatment with chemotherapy, prompting an examination of its functional contributions to resistance. We found that continuous exposure to IGF2 or insulin in the absence of serum created a dormant growth state in osteosarcoma cells that conferred resistance to various chemotherapeutic drugs in vitro. Mechanistic investigations revealed that this dormant state correlated with downregulation of downstream signaling by the IGF1 receptor, heightened cell survival, enhanced autophagy, and the presence of extracellular glutamine. Notably, inhibiting autophagy or depleting glutamine was sufficient to increase chemotherapeutic sensitivity in osteosarcoma xenografts in mice. Clinically, we confirmed that IGF expression levels were elevated in human osteosarcoma specimens from patients who received chemotherapy. Together, our results suggest that activation of IGF or insulin signaling preserves the survival of osteosarcoma cells under chemotherapeutic stress, providing a drug-resistant population that may engender minimal residual disease. Attenuating this survival mechanism may help overcome therapeutic resistance in osteosarcoma.


Asunto(s)
Autofagia/fisiología , Neoplasias Óseas/tratamiento farmacológico , Factor II del Crecimiento Similar a la Insulina/farmacología , Osteosarcoma/tratamiento farmacológico , Adolescente , Adulto , Animales , Neoplasias Óseas/patología , Línea Celular Tumoral , Supervivencia Celular , Niño , Citoprotección , Resistencia a Antineoplásicos , Femenino , Glutamina/metabolismo , Humanos , Insulina/farmacología , Factor II del Crecimiento Similar a la Insulina/análisis , Masculino , Ratones , Ratones Endogámicos C57BL , Osteosarcoma/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA